Nothing Special   »   [go: up one dir, main page]

IS7470A - Kínólínafleiður og notkun þeirra sem 5-HT6 tengla - Google Patents

Kínólínafleiður og notkun þeirra sem 5-HT6 tengla

Info

Publication number
IS7470A
IS7470A IS7470A IS7470A IS7470A IS 7470 A IS7470 A IS 7470A IS 7470 A IS7470 A IS 7470A IS 7470 A IS7470 A IS 7470A IS 7470 A IS7470 A IS 7470A
Authority
IS
Iceland
Prior art keywords
links
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
IS7470A
Other languages
English (en)
Other versions
IS2599B (is
Inventor
Ahmed Mahmood
Norbert Johnson Christopher
C. Jones Martin
James Macdonald Gregor
Frederick Moss Stephen
Thompson Mervyn
Edward Wade Charles
Witty David
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28456035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7470(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0207289A external-priority patent/GB0207289D0/en
Priority claimed from GB0225678A external-priority patent/GB0225678D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7470A publication Critical patent/IS7470A/is
Publication of IS2599B publication Critical patent/IS2599B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS7470A 2002-03-27 2004-09-24 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess IS2599B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207289A GB0207289D0 (en) 2002-03-27 2002-03-27 Novel compounds
GB0225678A GB0225678D0 (en) 2002-11-04 2002-11-04 Novel compounds
PCT/EP2003/003197 WO2003080580A2 (en) 2002-03-27 2003-03-25 Quinoline derivatives and their use as 5-ht6 ligands

Publications (2)

Publication Number Publication Date
IS7470A true IS7470A (is) 2004-09-24
IS2599B IS2599B (is) 2010-04-15

Family

ID=28456035

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7470A IS2599B (is) 2002-03-27 2004-09-24 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess

Country Status (28)

Country Link
US (5) US7452888B2 (is)
EP (2) EP1497266B1 (is)
JP (2) JP4455064B2 (is)
KR (1) KR101020399B1 (is)
CN (1) CN1315809C (is)
AR (1) AR039127A1 (is)
AT (1) ATE398108T1 (is)
AU (1) AU2003219103B2 (is)
BR (1) BRPI0308696B8 (is)
CA (1) CA2479786C (is)
CY (2) CY1108313T1 (is)
DE (1) DE60321558D1 (is)
DK (2) DK1497266T3 (is)
ES (2) ES2386828T3 (is)
HK (1) HK1074439A1 (is)
IL (2) IL164108A0 (is)
IS (1) IS2599B (is)
MX (1) MXPA04009318A (is)
MY (1) MY138836A (is)
NO (1) NO329319B1 (is)
NZ (1) NZ535239A (is)
PL (1) PL209872B1 (is)
PT (2) PT1956004E (is)
RU (1) RU2309154C9 (is)
SI (2) SI1956004T1 (is)
TW (1) TWI268928B (is)
WO (1) WO2003080580A2 (is)
ZA (1) ZA200407320B (is)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535239A (en) * 2002-03-27 2008-03-28 Glaxo Group Ltd Quinoline derivatives and their use as 5-HT6 ligands
NZ541699A (en) 2003-02-14 2009-01-31 Wyeth Corp Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
BRPI0407493A (pt) 2003-02-14 2006-02-14 Wyeth Corp derivados heterociclil-3-sulfinilazaindol ou -azaindazol como ligantes de 5-hidroxitriptamina-6
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
GB0322629D0 (en) * 2003-09-26 2003-10-29 Glaxo Group Ltd Novel compound
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
GB0425548D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
GB0426313D0 (en) * 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
BRPI0611516A2 (pt) 2005-06-02 2010-09-14 Hoffmann La Roche 3-metanossulfonilquinolinas como realçadores ("enhancers") de gaba-b
AU2006286654A1 (en) 2005-07-27 2007-03-08 F. Hoffmann-La Roche Ag 4-aryloxy quinoline derivatives as 5-HT6 modulators
GB0519765D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
GB0519760D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
GB0519758D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
JP2009520014A (ja) * 2005-12-20 2009-05-21 リヒター ゲデオン ニュルト ｍＧｌｕＲ５受容体介在障害の治療に有用なキノリン誘導体
EP2001865A1 (en) 2006-04-05 2008-12-17 Wyeth a Corporation of the State of Delaware Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
EA017007B1 (ru) 2007-01-08 2012-09-28 Сувен Лайф Сайенсиз Лимитед Соединения 5-(гетероциклил)алкил-n-(арилсульфонил)индола и их применение в качестве лигандов 5-ht
JP5550352B2 (ja) * 2007-03-15 2014-07-16 ノバルティス アーゲー 有機化合物およびその使用
JP2010521516A (ja) * 2007-03-21 2010-06-24 グラクソ グループ リミテッド 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用
RU2009139073A (ru) * 2007-03-23 2011-04-27 Эбботт Гмбх Унд Ко.Кг (De) Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-нт6
ATE513810T1 (de) 2007-05-03 2011-07-15 Suven Life Sciences Ltd Aminoalkoxy-aryl-sulfonamidverbindungen und ihre verwendung als 5-ht6-liganden
NZ581853A (en) * 2007-06-18 2012-11-30 Richter Gedeon Nyrt Sulfonyl-quinoline derivatives
AU2008285652B2 (en) 2007-08-07 2013-09-05 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
EA017154B1 (ru) 2007-10-26 2012-10-30 Сувен Лайф Сайенсиз Лимитед Аминоарилсульфонамидные соединения и их применение в качестве 5-нтлигандов
US9084742B2 (en) * 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
JP2011512340A (ja) * 2008-02-15 2011-04-21 エフ．ホフマン−ラ ロシュ アーゲー ３−アルキルピペラジン誘導体及びその使用
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
KR101308819B1 (ko) 2008-09-17 2013-09-13 수벤 라이프 사이언시스 리미티드 아릴 술폰아미드 아민 화합물 및 5-ｈｔ6 리간드로서의 용도
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
PT2448582T (pt) 2009-06-29 2017-07-10 Agios Pharmaceuticals Inc Compostos e composições terapêuticas
SG181976A1 (en) * 2010-01-04 2012-08-30 Nippon Soda Co Nitrogen-containing heterocyclic compound and agricultural fungicide
ES2552463T3 (es) 2010-01-05 2015-11-30 Suven Life Sciences Limited Compuestos aromáticos de sulfona útiles para el tratamiento de enfermedades del sistema nervioso central
RU2443697C1 (ru) * 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR101250606B1 (ko) * 2011-01-24 2013-04-03 이화여자대학교 산학협력단 5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AR086411A1 (es) 2011-05-20 2013-12-11 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
AU2012321345B2 (en) * 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2500672C1 (ru) * 2012-10-25 2013-12-10 Андрей Александрович Иващенко (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
US9302992B2 (en) 2013-04-02 2016-04-05 Annji Pharmaceutical Co., Ltd. Multifunctional quinoline derivatives as anti-neurodegenerative agents
JP6153179B2 (ja) 2013-04-02 2017-06-28 アンジー ファーマスーティカル シーオー．，エルティーディー．Ａｎｎｊｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 抗神経変性剤としての多機能キノリン誘導体
WO2016179569A1 (en) * 2015-05-07 2016-11-10 Axovant Sciences Ltd. Compositions and methods of treating a neurodegenerative disease
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
WO2017134280A1 (en) * 2016-02-05 2017-08-10 Pharnext Novel combinatorial therapies of neurological disorders
WO2017157929A1 (en) * 2016-03-14 2017-09-21 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
CN108290842B (zh) * 2016-05-27 2021-04-06 深圳市塔吉瑞生物医药有限公司 一种取代的喹啉化合物及其药物组合物
WO2018102824A1 (en) * 2016-12-02 2018-06-07 Axovant Sciences Gmbh Methods for treating neurodegenerative disease
KR20210076224A (ko) 2019-12-13 2021-06-24 주식회사 에피바이오텍 퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물
KR102281647B1 (ko) * 2020-12-09 2021-07-30 메디케어제약 주식회사 피페라진-퀴놀린 유도체의 제조방법

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US708469A (en) * 1901-08-27 1902-09-02 George Lafayette Caldwell Stroke-regulating mechanism for glass-presses, &c.
JPH02262627A (ja) 1988-12-08 1990-10-25 Japan Synthetic Rubber Co Ltd 有機非線形光学素子
SI9200377A (en) * 1992-12-11 1994-06-30 Krka Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation
GB9300147D0 (en) 1993-01-06 1993-03-03 Minnesota Mining & Mfg Photothermographic materials
GB9311790D0 (en) 1993-06-08 1993-07-28 Minnesota Mining & Mfg Photothermographic materials
US5596001A (en) 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
US5576338A (en) 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
AUPN842196A0 (en) 1996-03-05 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2750988B1 (fr) 1996-07-11 1998-09-18 Adir Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20010051719A1 (en) 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0867477B1 (de) 1997-03-25 2002-05-02 Ciba SC Holding AG Polycyclische Verbindungen
AU7644698A (en) 1997-04-22 1998-11-13 Janssen Pharmaceutica N.V. Crf antagonistic quino- and quinazolines
CZ298490B6 (cs) 1997-05-28 2007-10-17 Aventis Pharmaceuticals Inc. Chinolinová a chinoxalinová sloucenina, farmaceutický prostredek obsahující tuto slouceninu, použití této slouceniny a zpusob inhibování aktivity PDGF tyrosin­kinázy in vitro
JP2002505689A (ja) 1997-06-19 2002-02-19 セプレイコー インコーポレイテッド キノリン−インドール抗菌剤、それらに関する用途及び組成物
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US6103905A (en) 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en) 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
CA2296033A1 (en) 1997-07-11 1999-01-21 Smithkline Beecham P.L.C. Novel compounds
DE69906397T2 (de) * 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6403808B1 (en) 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
DE60004654T2 (de) 1999-03-29 2004-06-24 Neurogen Corp., Branford 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
DE69937372T2 (de) * 1999-04-21 2008-06-26 Nps Allelix Corp., Mississauga Piperidin-indol derivate mit 5-ht6 affinität
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
AU1542201A (en) 1999-11-05 2001-05-14 Nps Allelix Corp. Compounds having 5-HT6 receptor antagonist activity
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6310212B1 (en) 2000-03-28 2001-10-30 Neurogen Corporation 4-substituted quinoline derivatives
PE20020063A1 (es) 2000-06-20 2002-01-30 Upjohn Co Bis-arilsulfonas como ligandos del receptor de 5-ht
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
GB0021450D0 (en) 2000-08-31 2000-10-18 Smithkline Beecham Plc Novel compounds
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
CZ20031145A3 (cs) 2000-10-02 2003-12-17 Janssen Pharmaceutica N.V. Antagonisté metabotropního glutamátového receptoru
CA2422717A1 (en) 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
EP1343756A2 (en) 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US6849644B2 (en) 2000-11-21 2005-02-01 Smithkline Beecham P.L.C. Isoquinoline derivatives useful in the treatment of CNS disorders
ATE337780T1 (de) 2000-11-24 2006-09-15 Smithkline Beecham Plc Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
EP1401813B1 (en) 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
WO2002102774A1 (en) 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
MXPA04001089A (es) 2001-08-03 2004-05-20 Upjohn Co 5-arilsulfonil indoles que tienen afinidad por el receptor de 5-ht.
JP2005527463A (ja) 2001-08-07 2005-09-15 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン
DE60230424D1 (en) 2001-08-10 2009-01-29 Hoffmann La Roche Arylsulfonyl-derivate mit 5-ht 6-rezeptor-affinität
DK1425272T3 (da) 2001-08-31 2011-11-21 Novartis Ag Optiske isomerer af en iloperidon-metabolit
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
EP1456178A1 (en) 2001-12-21 2004-09-15 Smithkline Beecham Plc 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
EP1471912A1 (en) 2002-02-05 2004-11-03 Glaxo Group Limited Method of promoting neuronal growth
GB0202679D0 (en) 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
ATE323680T1 (de) 2002-02-13 2006-05-15 Glaxo Group Ltd 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
DE10207844A1 (de) 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
EP1478361A2 (en) 2002-02-22 2004-11-24 PHARMACIA & UPJOHN COMPANY Arylsulfone derivatives
JP2005527542A (ja) 2002-03-27 2005-09-15 グラクソ　グループ　リミテッド キノリンおよびアザインドール誘導体およびその５−ｈｔ６リガンドとしての使用
NZ535239A (en) * 2002-03-27 2008-03-28 Glaxo Group Ltd Quinoline derivatives and their use as 5-HT6 ligands
AU2003233231B2 (en) 2002-05-13 2009-02-26 F. Hoffmann-La Roche Ag Benzoxazine derivatives as 5-HT6 modulators and uses thereof
DE10221183A1 (de) 2002-05-13 2003-12-04 Max Planck Gesellschaft Phosphatidyl-oligo-glycerine und Strukturanaloga
PL374401A1 (en) 2002-06-05 2005-10-17 F.Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
EA008835B1 (ru) 2002-06-20 2007-08-31 Биовитрум Аб Замещенные сульфоны и сульфонамиды и фармацевтические композиции на их основе, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
RU2326112C2 (ru) 2002-09-17 2008-06-10 Ф.Хоффманн-Ля Рош Аг 2,4-замещенные индолы и фармацевтическая композиция, обладающая антагонистической активностью к 5-гт6 рецептору
ATE362469T1 (de) 2002-09-17 2007-06-15 Hoffmann La Roche 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
WO2004035047A1 (en) 2002-10-18 2004-04-29 F. Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
WO2004041792A1 (en) 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted benzoxazinones and uses thereof
CN1713908B (zh) 2002-12-03 2010-05-12 弗·哈夫曼-拉罗切有限公司 作为5-ht6-受体配体用于治疗中枢神经系统病症的氨基烷氧基吲哚
BRPI0407493A (pt) 2003-02-14 2006-02-14 Wyeth Corp derivados heterociclil-3-sulfinilazaindol ou -azaindazol como ligantes de 5-hidroxitriptamina-6
ES2297386T3 (es) 2003-03-03 2008-05-01 F. Hoffmann-La Roche Ag Tetrahidroisoquinolinas 2,5-sustituidas para uso como moduladores de 5-ht6.
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
GB0320320D0 (en) 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
GB0322629D0 (en) 2003-09-26 2003-10-29 Glaxo Group Ltd Novel compound
GB0407025D0 (en) 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
GB0422263D0 (en) 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
GB0519760D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
GB0519765D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
TWI268928B (en) 2006-12-21
US20090036682A1 (en) 2009-02-05
US20100305107A1 (en) 2010-12-02
ZA200407320B (en) 2005-11-30
CY1108313T1 (el) 2014-02-12
WO2003080580A3 (en) 2004-02-05
SI1956004T1 (sl) 2012-09-28
DE60321558D1 (de) 2008-07-24
EP1956004B1 (en) 2012-06-13
EP1956004A1 (en) 2008-08-13
EP1497266B1 (en) 2008-06-11
SI1497266T1 (sl) 2008-10-31
US7452888B2 (en) 2008-11-18
IL164108A0 (en) 2005-12-18
KR20040094874A (ko) 2004-11-10
AU2003219103B2 (en) 2008-10-23
IL164108A (en) 2010-05-31
DK1497266T3 (da) 2008-10-06
BRPI0308696B8 (pt) 2021-05-25
MY138836A (en) 2009-07-31
ES2386828T3 (es) 2012-08-31
KR101020399B1 (ko) 2011-03-08
WO2003080580A2 (en) 2003-10-02
HK1074439A1 (en) 2005-11-11
AR039127A1 (es) 2005-02-09
ATE398108T1 (de) 2008-07-15
CN1656075A (zh) 2005-08-17
US8236947B2 (en) 2012-08-07
US20050124628A1 (en) 2005-06-09
US20090298841A1 (en) 2009-12-03
US7799774B2 (en) 2010-09-21
BR0308696A (pt) 2005-01-25
TW200403224A (en) 2004-03-01
JP5091913B2 (ja) 2012-12-05
NZ535239A (en) 2008-03-28
RU2309154C2 (ru) 2007-10-27
IS2599B (is) 2010-04-15
BRPI0308696A8 (pt) 2017-04-11
CA2479786A1 (en) 2003-10-02
ES2307919T3 (es) 2008-12-01
EP1497266A2 (en) 2005-01-19
CY1113306T1 (el) 2016-04-13
US7977337B2 (en) 2011-07-12
JP2005531518A (ja) 2005-10-20
DK1956004T3 (da) 2012-08-06
JP4455064B2 (ja) 2010-04-21
BRPI0308696B1 (pt) 2019-07-16
PT1956004E (pt) 2012-08-31
PL374378A1 (en) 2005-10-17
AU2003219103A1 (en) 2003-10-08
NO329319B1 (no) 2010-09-27
RU2309154C9 (ru) 2016-09-27
CN1315809C (zh) 2007-05-16
PL209872B1 (pl) 2011-10-31
US20110237792A1 (en) 2011-09-29
US7601837B2 (en) 2009-10-13
JP2009235080A (ja) 2009-10-15
RU2004131641A (ru) 2005-06-27
PT1497266E (pt) 2008-09-10
CA2479786C (en) 2011-11-29
MXPA04009318A (es) 2005-01-25
NO20044588L (no) 2004-10-25

Similar Documents

Publication Publication Date Title
IS7470A (is) Kínólínafleiður og notkun þeirra sem 5-HT6 tengla
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
NO20052524D0 (no) Aminerte isofiavonoidderivater og anvendelse derav
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
IS7376A (is) N-arýl-2-oxasólidínón-5-karboxamið og afleiður þeirra og notkun þeirra sem bakteríueyðandi efni
IS7749A (is) Pýrimídínafleiður og notkun þeirra sem CB2 beina
IS7701A (is) Arípíprazól samsett lyfjaform og aðferð
IS7948A (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
IS7926A (is) 4-útskipt bensímídasól og notkun þeirra sem magasýruseytishemla
ATE390426T1 (de) Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate
IS7944A (is) 1,5-díarýl-pýrról-3-karboxamíðafleiður og notkun þeirra sem stilla kannabisefnaviðtaka
IS7427A (is) 3-sýklýl-5-(5-hluta hringur sem inniheldur köfnunarefni) metýl-oxasólídínónafleiður og notkun þeirra sem bakteríueyðandi efna
IS7575A (is) Própíónsýruafleiður og notkun þeirra sem HPPAR virkjar
FI20020001A0 (fi) Palonsammutusmenetelmõ ja -laitteisto
DE60330269D1 (de) Piperazinyl- und diazapanylbenzamide und-benzothioamide
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
DK1663982T3 (da) Aminoquinolinderivater og deres anvendelse som adenosin-A3-ligander
IS8220A (is) Bensímídasólafleiður, blöndur sem innihalda þær, framleiðsla þeirra og notkun
IS2773B (is) Amínókínólínafleiður og notkun þeirra sem adenósín A3-bindlar
SI1551814T1 (sl) Derivati kiralne oksazol-arilpropionske kisline in njihova uporaba kot ppar-agonisti
IS2490B (is) Bensóþíasól- og bensoxasól-4,7-díonafleiður og notkun þeirra sem cdc25 fosfatasatálma